Summary of Populations

(All Subjects)

Population

Placebo

Xanomeline

High Dose

Xanomeline

Low Dose

Total

Intent-To-Treat

86 (100%)

84 (100%)

254 (100%)

Safety Set

86 (100%)

84 (100%)

254 (100%)

Efficacy Set

79 (91.9%)

81 (96.4%)

74 (88.1%)

234 (92.1%)

Complete Week 8

74 (86%)

60 (71.4%)

56 (66.7%)

190 (74.8%)

Complete Week 16

68 (79.1%)

42 (50%)

37 (44%)

147 (57.9%)

Complete Week 24

60 (69.8%)

28 (33.3%)

30 (35.7%)

118 (46.5%)

Completion Study

58 (67.4%)

25 (29.8%)

27 (32.1%)

110 (43.3%)

NOTE: N in column headers represents number of subjects entered in study (i.e., signed informed consent). The ITT population includes all

subjects randomized. The Safety population includes all randomized subjects known to have taken at least one dose of randomized study

drug. The Efficacy population includes all subjects in the safety population who also have at least one post-baseline ADAS-Cog and

CIBIC+ assessment.